Premium
Butyrate‐Loaded Chitosan/Hyaluronan Nanoparticles: A Suitable Tool for Sustained Inhibition of ROS Release by Activated Neutrophils
Author(s) -
Sacco Pasquale,
Decleva Eva,
Tentor Fabio,
Menegazzi Renzo,
Borgogna Massimiliano,
Paoletti Sergio,
Kristiansen Kåre Andre,
Vårum Kjell Morten,
Marsich Eleonora
Publication year - 2017
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201700214
Subject(s) - butyrate , reactive oxygen species , chemistry , hyaluronic acid , chitosan , internalization , inflammation , hypochlorous acid , biochemistry , microbiology and biotechnology , biophysics , cell , immunology , medicine , biology , fermentation , anatomy
Abstract Tissue damage caused by excessive amounts of neutrophil‐derived reactive oxygen species (ROS) occurs in many inflammatory diseases. Butyrate is a short‐chain fatty acid (SCFA) with known anti‐inflammatory properties, able to modulate several neutrophil functions. Evidence is provided here that butyrate inhibits neutrophil ROS release in a dose and time‐dependent fashion. Given the short half‐life of butyrate, chitosan/hyaluronan nanoparticles are next designed and developed as controlled release carriers able to provide cells with a long‐lasting supply of this SCFA. Notably, while the inhibition of neutrophil ROS production by free butyrate declines over time, that of butyrate‐loaded chitosan/hyaluronan nanoparticles (B‐NPs) is sustained. Additional valuable features of these nanoparticles are inherent ROS scavenger activity, resistance to cell internalization, and mucoadhesiveness. B‐NPs appear as promising tools to limit ROS‐dependent tissue injury during inflammation. Particularly, by virtue of their mucoadhesiveness, B‐NPs administered by enema can be effective in the treatment of inflammatory bowel diseases.